Centro de Estudios Clínicos e Investigaciones Médicas CeCim
Centro de Estudios Clínicos e Investigaciones Médicas CeCim
Paseo Bulnes 79, oficina 27, Santiago, Región Metropolitana
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Raul Moroni
Carla Saavedra
Francisca Castillo
Ximena Fonck
Carla Andrea Cueto Pino
Open studies
Lupus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST) - AMETHYST - BiogenSee more
A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus - GALACELA - Galapagos NVSee more
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) - Merck Sharp & Dohme LLCSee more
Crohn's disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease - CULTIVATE - Arena PharmaceuticalsSee more
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) - Merck Sharp & Dohme LLCSee more
Cardiac arrhythmia
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation - LIBREXIA-AF - Janssen Research & Development, LLCSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma - LOTIS 5 - ADC Therapeutics S.A.See more
Ulcerative colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - Merck Sharp & Dohme LLCSee more
